Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression-Reference-Cited by-同舟云学术

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression

Published:2021-11-16 Issue:2 Volume:38 Page:157-164
ISSN:1607-551X
Container-title:The Kaohsiung Journal of Medical Sciences
language:en
Short-container-title:The Kaohsiung J of Med Scie

Author:

Lin Zu‐Yau¹²³^ORCID,Yeh Ming‐Lun¹²³,Huang Ching‐I¹²³,Chen Shinn‐Cherng⁴,Huang Chung‐Feng¹²³^ORCID,Huang Jee‐Fu¹²³^ORCID,Dai Chia‐Yen¹²³,Yu Ming‐Lung¹²³,Chuang Wan‐Long¹²³

Affiliation:

1. Division of Hepatobiliary Medicine, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan

2. Department of Internal Medicine, Faculty of Medicine, College of Medicine Kaohsiung Medical University Kaohsiung Taiwan

3. Center for Cancer Research Kaohsiung Medical University Kaohsiung Taiwan

4. Department of Internal Medicine Kaohsiung Municipal Ta‐Tung Hospital Kaohsiung Taiwan

Funder

Kaohsiung Medical University Chung-Ho Memorial Hospital

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/kjm2.12471

Reference27 articles.

1. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2. Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

3. Sorafenib

4. Modulation of Autophagy by Sorafenib: Effects on Treatment Response

5. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma;Biomedicine & Pharmacotherapy;2022-09